نتایج جستجو برای: fgfr3

تعداد نتایج: 1106  

Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods: A retrospective study was undertaken on paraffin blocks o...

Journal: :Sensors and Actuators B-chemical 2021

Fibroblast growth factor receptor 3 (FGFR3) is a transmembrane tyrosine kinase protein in the fibroblast family, which plays key role many biological processes. Over-expression and activating mutations FGFR3 are frequent non-invasive bladder cancer, highlighting this as potential biomarker for recurrent cancer detection. Affimer reagents isolated against recombinant were assessed their affinity...

Journal: :Therapeutics and Clinical Risk Management 2005
Shenxian Qian George Somlo Bingsen Zhou Yun Yen

Thalidomide (Thal), a novel agent in the treatment of multiple myeloma, is presumed to act through a variety of mechanisms. In the present study, we examined the relationship between fibroblast growth factor receptor 3 (FGFR3) expression and the therapeutic effect of Thal. The DNA synthesis of KMS-11 clone, which overexpresses FGFR3, was inhibited by Thal in a dose-dependent manner; whereas U26...

Journal: :The Biochemical journal 2002
Sujata G Pandit Prasanthi Govindraj Joachim Sasse Peter J Neame John R Hassell

Point mutations in the human fibroblast growth factor (FGF) receptor 3 gene (Fgfr3) produce a constitutively active receptor, which disrupts chondrocyte differentiation in the growth plate and results in skeletal dysplasias with severe shortening of the limbs. Alternative splicing of the Fgfr3 transcript gives rise to two isoforms, IIIc and IIIb, which vary in their specificity for FGF ligands....

2015
CÉDRIC POYET THOMAS HERMANNS QING ZHONG EVA DRESCHER DANIEL EBERLI MAXIMILIAN BURGER FERDINAND HOFSTAEDTER ARNDT HARTMANN ROBERT STÖHR ELLEN C. ZWARTHOFF TULLIO SULSER PETER J. WILD

In addition to conventional clinicopathological parameters, molecular markers are also required in order to predict the course of disease in patients with urothelial bladder cancer (BC). Little is known about fibroblast growth factor receptor 3 (FGFR3) immunoreactivity and the clinical significance it may possess with regard to BC. The present study aimed to investigate the immunoreactivity of ...

2016
Masahiro Kurobe Takahiro Kojima Kouichi Nishimura Shuya Kandori Takashi Kawahara Takayuki Yoshino Satoshi Ueno Yuichi Iizumi Koji Mitsuzuka Yoichi Arai Hiroshi Tsuruta Tomonori Habuchi Takashi Kobayashi Yoshiyuki Matsui Osamu Ogawa Mikio Sugimoto Yoshiyuki Kakehi Yoshiyuki Nagumo Masakazu Tsutsumi Takehiro Oikawa Koji Kikuchi Hiroyuki Nishiyama

INTRODUCTION AND OBJECTIVES Oncogenic FGFR3-TACC3 fusions and FGFR3 mutations are target candidates for small molecule inhibitors in bladder cancer (BC). Because FGFR3 and TACC3 genes are located very closely on chromosome 4p16.3, detection of the fusion by DNA-FISH (fluorescent in situ hybridization) is not a feasible option. In this study, we developed a novel RNA-FISH assay using branched DN...

Journal: :Molecular cancer therapeutics 2013
Kilian M Gust David J McConkey Shannon Awrey Paul K Hegarty Jing Qing Jolanta Bondaruk Avi Ashkenazi Bogdan Czerniak Colin P Dinney Peter C Black

Activating mutations of fibroblast growth factor receptor-3 (FGFR3) have been described in approximately 75% of low-grade papillary bladder tumors. In muscle-invasive disease, FGFR3 mutations are found in 20% of tumors, but overexpression of FGFR3 is observed in about half of cases. Therefore, FGFR3 is a particularly promising target for therapy in bladder cancer. Up to now, most drugs tested f...

Journal: :Human molecular genetics 2014
Federico Di Rocco Martin Biosse Duplan Yann Heuzé Nabil Kaci Davide Komla-Ebri Arnold Munnich Emilie Mugniery Catherine Benoist-Lasselin Laurence Legeai-Mallet

FGFR3 gain-of-function mutations lead to both chondrodysplasias and craniosynostoses. Achondroplasia (ACH), the most frequent dwarfism, is due to an FGFR3-activating mutation which results in impaired endochondral ossification. The effects of the mutation on membranous ossification are unknown. Fgfr3(Y367C/+) mice mimicking ACH and craniofacial analysis of patients with ACH and FGFR3-related cr...

Journal: :The Journal of biological chemistry 2011
Lijuan He Nadia Shobnam William C Wimley Kalina Hristova

The G380R mutation in the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) causes achondroplasia, the most common form of human dwarfism. Achondroplasia is a heterozygous disorder, and thus the affected individuals express both wild-type and mutant FGFR3. Yet heterodimerization in achondroplasia has not been characterized thus far. To investigate the formation of FGFR3 hetero...

Journal: :Cancer research 2005
Darren C Tomlinson Corine G L'Hôte Wendy Kennedy Eva Pitt Margaret A Knowles

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that play key roles in proliferation, differentiation, and tumorigenesis. FGFR3 was identified as the major family member expressed in both normal human urothelium and cultured normal human urothelial (NHU) cells and was expressed as the IIIb isoform. We also identified a splice variant, FGFR3 Delta8-10, lackin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید